Skip to main content
Qurient Co., Ltd. logo

Qurient Co., Ltd. — Investor Relations & Filings

Ticker · 115180 ISIN · KR7115180002 KO Professional, scientific and technical activities
Open in API
Filings indexed 437 across all filing types
Latest filing 2023-12-05 Capital/Financing Update
Country KR South Korea
Listing KO 115180

About Qurient Co., Ltd.

http://www.qurient.com/

Qurient Co., Ltd. is a clinical-stage biopharmaceutical company focused on developing innovative therapeutics for unmet medical needs. The company operates on a proprietary 'Network R&D' model, a virtual approach that manages drug development programs from early discovery through clinical phases. Its pipeline includes Adrixetinib for chronic graft-versus-host disease (cGvHD), Telacebec for the treatment of tuberculosis, and a next-generation dual-payload Antibody-Drug Conjugate (ADC) platform for oncology. Qurient advances its portfolio through global clinical trials and strategic collaborations to address critical diseases.

Recent filings

Filing Released Lang Actions
[발행조건확정]증권신고서(지분증권)
Capital/Financing Update Classification · 98% confidence The document is a 'Securities Registration Statement' (증권신고서) filed with the Financial Services Commission in South Korea. It specifically details the finalization of issuance terms (발행조건확정) for a capital increase (유상증자). The document contains detailed tables regarding the final issue price, number of shares, and the impact on the company's financial risk profile (e.g., management of administrative issues). Since this is a formal regulatory filing for a capital change/share issuance that has been amended to reflect final pricing, it falls under the 'Share Issue/Capital Change' category.
2023-12-05 Korean
[기재정정]투자설명서
Capital/Financing Update Classification · 95% confidence The document is a '투자설명서 정정신고' (Amendment to Investment Prospectus) filed by Qurient Co., Ltd. It details changes to the offering price, total proceeds, and associated risk factors following the finalization of the issuance price for a capital raise (rights offering). This is a formal regulatory filing related to securities issuance and capital structure, which falls under the 'Proxy Solicitation & Information Statement' (PSI) category in many financial databases as it serves as the primary disclosure document for shareholders regarding new share offerings, or alternatively, it is a core regulatory filing. Given the specific options, 'PSI' is the most accurate classification for a prospectus/offering document.
2023-12-05 Korean
[기재정정]투자설명서
Investor Presentation Classification · 95% confidence The document is a 'Correction Report' (정정신고) for an 'Investment Prospectus' (투자설명서) filed by Qurient Co., Ltd. It details specific amendments made to the previously filed prospectus, including updates to the offering schedule, share allocation ratios, and risk factors following the submission of the Q3 report and financial statement review. Since this is a formal regulatory filing related to a securities offering (capital raise), it falls under the category of 'Share Issue/Capital Change' (SHA) as it pertains to the issuance of new shares and the associated prospectus documentation.
2023-11-27 Korean
[기재정정]증권신고서(지분증권) (2023.12)
Share Issue/Capital Change Classification · 95% confidence The document is a 'Securities Registration Statement' (증권신고서) amendment filed by Curient Co., Ltd. It details corrections made to a previously submitted registration statement, specifically addressing financial statement review findings by the Financial Supervisory Service (FSS). This type of regulatory filing, which amends the terms and disclosures of a securities offering, falls under the category of Regulatory Filings (RNS) as it is a formal submission to a regulatory body that does not fit into the other specific categories like 10-K or Earnings Release.
2023-11-17 Korean
[기재정정]사업보고서 (2021.12)
Audit Report / Information Classification · 100% confidence The document is a 'Consolidated Audit Report' (연결감사보고서) for Curient Inc. (주식회사 큐리언트). It contains the independent auditor's report, consolidated financial statements (balance sheet, income statement, statement of changes in equity, cash flow statement), and detailed notes. It is a comprehensive financial report covering a full fiscal year (2021), not an announcement or a summary. Therefore, it is classified as an Audit Report (AR). FY 2021
2023-11-15 Korean
[기재정정]사업보고서 (2022.12)
Audit Report / Information Classification · 100% confidence The document is a 'Consolidated Audit Report' (연결감사보고서) for the company QLi5 Therapeutics GmbH and its parent company, Curient. It includes the independent auditor's report, consolidated financial statements (balance sheet, income statement, statement of changes in equity, cash flow statement), and detailed notes. Although it mentions a 'correction' (정정) at the beginning, the core content is the full audited financial report for the fiscal year 2022. This fits the definition of an Audit Report (AR) as it provides the standalone audit results and financial statements. FY 2022
2023-11-15 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.